Balance Sheet
Accounts PayablesAssetsCommon EquityLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Exousia Bio (LMMY) Assets (2023 - 2025)

Lamy (LMMY) has disclosed Assets for 3 consecutive years, with $22.1 million as the latest value for Q4 2025.

  • Quarterly Assets rose 88620.81% to $22.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.1 million through Nov 2025, up 88620.81% year-over-year, with the annual reading at $27453.0 for FY2024, 25.89% down from the prior year.
  • Assets hit $22.1 million in Q4 2025 for Lamy, up from $24854.0 in the prior quarter.
  • In the past five years, Assets ranged from a high of $22.1 million in Q4 2025 to a low of $24854.0 in Q4 2024.
  • Historically, Assets has averaged $2.5 million across 3 years, with a median of $27453.0 in 2024.
  • Biggest five-year swings in Assets: dropped 27.24% in 2024 and later skyrocketed 88620.81% in 2025.
  • Year by year, Assets stood at $26742.0 in 2023, then dropped by 7.06% to $24854.0 in 2024, then surged by 88620.81% to $22.1 million in 2025.
  • Business Quant data shows Assets for LMMY at $22.1 million in Q4 2025, $24854.0 in Q4 2024, and $27958.0 in Q3 2024.